Ratings Eiken Chemical Co., Ltd.

Equities

4549

JP3160700005

Market Closed - Japan Exchange Other stock markets 11:30:00 13/05/2024 am IST			5-day change	1st Jan Change
2,073 ^JPY	+1.57%		+2.12%	+21.30%

21/03	Tranche Update on Eiken Chemical Co., Ltd.'s Equity Buyback Plan announced on January 30, 2024.	CI
19/03	Eiken Chemical Co., Ltd.'s Equity Buyback announced on January 30, 2024, has closed with 2,500,000 shares, representing 6.74% for ¥4,636.95 million.	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company benefits from high valuations in earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
EIKEN CHEMICAL CO., LTD.	+21.30%	45Cr	-
ABBOTT LABORATORIES	-4.84%	18TCr	C+
MEDTRONIC PLC	+0.56%	11TCr	C
BECTON, DICKINSON AND COMPANY	-3.35%	6.81TCr	A
DEXCOM, INC.	+2.39%	5.05TCr	B-
CENCORA, INC.	+9.36%	4.48TCr	B-
HOYA CORPORATION	+2.84%	4.07TCr	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+24.51%	3.23TCr	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	2.65TCr	A-
TERUMO CORPORATION	+15.25%	2.5TCr	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes